



CsrA Enhances Cyclic-di-GMP Biosynthesis and *Yersinia pestis* Biofilm Blockage of the Flea Foregut by Alleviating Hfq-Dependent Repression of the *hmsT* mRNA

Amelia R. Silva-Rohwer,^a Kiara Held,^a Janelle Sagawa,^a Nicolas L. Fernandez,^b Christopher M. Waters,^b  Viveka Vadyvaloo^a

^aPaul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA

^bDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA

ABSTRACT Plague-causing *Yersinia pestis* is transmitted through regurgitation when it forms a biofilm-mediated blockage in the foregut of its flea vector. This biofilm is composed of an extracellular polysaccharide substance (EPS) produced when cyclic-di-GMP (c-di-GMP) levels are elevated. The *Y. pestis* diguanylate cyclase enzymes HmsD and HmsT synthesize c-di-GMP. HmsD is required for biofilm blockage formation but contributes minimally to *in vitro* biofilms. HmsT, however, is necessary for *in vitro* biofilms and contributes to intermediate rates of biofilm blockage. C-di-GMP synthesis is regulated at the transcriptional and posttranscriptional levels. In this, the global RNA chaperone, Hfq, posttranscriptionally represses *hmsT* mRNA translation. How c-di-GMP levels and biofilm blockage formation is modulated by nutritional stimuli encountered in the flea gut is unknown. Here, the RNA-binding regulator protein CsrA, which controls c-di-GMP-mediated biofilm formation and central carbon metabolism responses in many Gammaproteobacteria, was assessed for its role in *Y. pestis* biofilm formation. We determined that CsrA was required for markedly greater c-di-GMP and EPS levels when *Y. pestis* was cultivated on alternative sugars implicated in flea biofilm blockage metabolism. Our assays, composed of mobility shifts, quantification of mRNA translation, stability, and abundance, and epistasis analyses of a *csrA hfq* double mutant strain substantiated that CsrA represses *hfq* mRNA translation, thereby alleviating Hfq-dependent repression of *hmsT* mRNA translation. Additionally, a *csrA* mutant exhibited intermediately reduced biofilm blockage rates, resembling an *hmsT* mutant. Hence, we reveal CsrA-mediated control of c-di-GMP synthesis in *Y. pestis* as a tiered, posttranscriptional regulatory process that enhances biofilm blockage-mediated transmission from fleas.

IMPORTANCE *Yersinia pestis*, the bacterial agent of bubonic plague, produces a c-di-GMP-dependent biofilm-mediated blockage of the flea vector foregut to facilitate its transmission by flea bite. However, the intricate molecular regulatory processes that underlie c-di-GMP-dependent biofilm formation and thus, biofilm-mediated blockage in response to the nutritional environment of the flea are largely undefined. This study provides a novel mechanistic understanding of how CsrA transduces alternative sugar metabolism cues to induce c-di-GMP-dependent biofilm formation required for efficient *Y. pestis* regurgitative transmission through biofilm-mediated flea foregut blockage. The *Y. pestis*-flea interaction represents a unique, biologically relevant, *in vivo* perspective on the role of CsrA in biofilm regulation.

KEYWORDS *Yersinia pestis*, *Xenopsylla cheopis* fleas, carbon storage regulator, c-di-GMP

Yersinia pestis evolved clonally from the gastrointestinal pathogen *Yersinia pseudotuberculosis* to be transmitted via flea bite (1–3). Within the flea gut, *Y. pestis* derives its nutrition from the bloodmeal and by-products of blood digestion to multiply and form a cohesive biofilm (4, 5). This enables development of a biofilm-mediated

Citation Silva-Rohwer AR, Held K, Sagawa J, Fernandez NL, Waters CM, Vadyvaloo V. 2021. CsrA enhances cyclic-di-GMP biosynthesis and *Yersinia pestis* biofilm blockage of the flea foregut by alleviating Hfq-dependent repression of the *hmsT* mRNA. mBio 12:e01358-21. <https://doi.org/10.1128/mBio.01358-21>.

Editor Michele S. Swanson, University of Michigan-Ann Arbor

Copyright © 2021 Silva-Rohwer et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Viveka Vadyvaloo, vvadyvaloo@wsu.edu.

Received 9 May 2021

Accepted 30 June 2021

Published 3 August 2021

blockage of the flea foregut. Blockage facilitates regurgitation of bacteria back into the flea bite site of the mammalian host to cause plague (3, 6).

Biofilms are multicellular bacterial communities encased in self-produced extracellular polymeric substances (EPS). Poly- β -1,6-*N*-acetyl-D-glucosamine exopolysaccharides (PNAG) comprise the *Y. pestis* EPS and are synthesized and exported by the gene products of the *hmsHFRS* operon (7, 8). The *hmsHFRS* operon is highly transcribed at flea optimal temperatures of $\leq 26^{\circ}\text{C}$, and the gene products are produced at elevated c-di-GMP levels (9, 10). In many bacteria, the planktonic/sessile and biofilm-producing states are directed by low or high levels of c-di-GMP, respectively (11–13). In the case of *Y. pestis*, three of the four discrete genetic changes that confer the trait of biofilm-mediated blockage transmissibility to this pathogen occur in loci involved in c-di-GMP metabolism (14, 15).

C-di-GMP is synthesized by diguanylate cyclases (DGCs) and degraded by phosphodiesterase (PDE) enzymes. Two DGCs, encoded by *hmsT* and *hmsD*, and one PDE encoded by *hmsP*, modulate c-di-GMP synthesis and hydrolysis, respectively, and are involved in biofilm production in *Y. pestis* (16–20). Although *hmsT* and *hmsD* have comparable transcript levels *in vitro* and in fleas (20), HmsD is predominantly involved in c-di-GMP synthesis in the flea. An *hmsD* mutant is severely impaired in biofilm-mediated flea blockage but exhibits only small reductions in *in vitro* biofilm formation (19, 20). Conversely, HmsT is the predominant DGC for *in vitro* biofilms. An *hmsT* mutant produces little to no biofilm *in vitro* and exhibits intermediate flea blockage rates (17, 20, 21). HmsT protein abundance is regulated at the transcriptional and posttranscriptional levels, while HmsD protein abundance is regulated posttranslationally. Hfq, the global RNA binding protein, posttranscriptionally represses *hmsT* mRNA (22, 23), while the Rcs phosphorelay system response regulator protein, RcsB, inhibits *hmsT* gene expression (24). HmsD is part of the HmsCDE locus encoding a tripartite signaling system, wherein HmsD is inversely modulated by HmsC and HmsE proteins in response to specific environmental stimuli (16, 19).

How *Y. pestis* integrates nutritional stimuli encountered in the flea gut to modulate c-di-GMP synthesis is unknown. The carbon storage regulator protein, CsrA, therefore was of interest because it posttranscriptionally coordinates physiological adaptations to changing nutritional environments in many bacteria. Additionally, the *csrA* gene is highly transcribed in *Y. pestis* blocked fleas (4). CsrA is a widely conserved global RNA binding protein in Gammaproteobacteria species, where it functions to modulate central carbon metabolism, cellular development, and pathogenesis and exhibits well-defined involvement in regulating biofilm formation (25–36). CsrA binds to the GGA motifs within 5' untranslated regions (5'UTR) of target mRNAs to alter their translation (37–41). Two noncoding RNAs (ncRNAs), CsrB and CsrC, containing numerous CsrA binding motifs, sequester and antagonize CsrA activity by competing for binding with target mRNAs (30).

CsrA primarily posttranscriptionally represses mRNA targets that activate biofilm formation in bacteria (25, 31, 36, 42, 43). However, CsrA positively regulates *in vitro* biofilm production in *Y. pestis* by an undefined mechanism (44). Here, we sought to determine if CsrA has a role in the physiologically relevant context of *in vivo* biofilm-mediated flea blockage. We determined that CsrA promoted *in vitro* biofilm production more stringently when alternative sugars implicated in flea biofilm formation were supplemented in the culture medium. Additionally, we identified that the mechanism by which CsrA positively regulated biofilm production was through translational inhibition of the *hfq* mRNA, which posttranscriptionally represses the *hmsT* mRNA required for c-di-GMP biosynthesis. Lastly, we determined that *Y. pestis* CsrA is needed for robust biofilm-mediated blockage of the transmission-proficient rat flea, *Xenopsylla cheopis*.

RESULTS

CsrA positively regulates *in vitro* EPS and intracellular c-di-GMP levels. Biofilm formation of a *Y. pestis* *csrA* mutant is impaired during growth on alternative carbon

sources (e.g., K-gluconate) versus the primary carbon source glucose (44). The alternative sugars ribose and galactose appear to be primarily catabolized by *Y. pestis* during flea blockage (4, 5). Hence, we tested if biofilm EPS formation in a *csrA* mutant is more drastically impaired in these biologically relevant sugars versus glucose. An assay based on the specificity of Congo red (CR) dye to polysaccharides (17, 45) was used to allow direct comparison of EPS production from different carbon sources through normalization by bacterial biomass. The assay media were HIB, a rich routine culture medium, and the chemically defined medium TMH (46), supplemented with either glucose (TMH-glu), ribose (TMH-rib), or galactose (TMH-gal).

A *csrA* mutant ($\Delta csrA$) generated previously (44) in the avirulent epidemic KIM6+ strain background, with an isogenic wild-type (WT) parent strain and a *cis*-complemented *csrA* mutant strain ($\Delta csrA::csrA$), were tested for EPS production. EPS production by the WT strain in HIB was >10-fold less than that in TMH medium regardless of the carbon source (Fig. 1A). EPS production in the WT strain was significantly lower in TMH-glu versus TMH-gal and TMH-rib. Under all conditions, a $\Delta hmsR$ strain, used as a negative control as it is unable to produce EPS, displayed little to no CR binding. Compared to the WT strain, the $\Delta csrA$ strain had significantly reduced EPS levels under all conditions, a phenotype that was restored in the $\Delta csrA::csrA$ strain. Mean reduction in EPS levels for the $\Delta csrA$ strain relative to the WT strain were 24% and 40% in HIB and TMH-glu and 87% and 81% in TMH-rib and TMH-gal, respectively.

To assess if EPS levels in the $\Delta csrA$ strain correlated with intracellular c-di-GMP pools, we quantified c-di-GMP in strains grown in TMH-glu, TMH-gal, and TMH-rib. The c-di-GMP levels of the WT strain ranged between 7.6 and 10.4, 63.4 to 107.8, and 63.6 to 117.8 pmol/mg cell weight in TMH-glu, TMH-gal, and TMH-rib, respectively (Fig. 1B). Under all conditions, a $\Delta hmsT$ strain, dysfunctional in c-di-GMP synthesis (19), produced little to no c-di-GMP, as expected (18, 19, 22). Compared to the WT strain, the $\Delta csrA$ strain had 2.7-, 8.2-, and 42-fold mean reduction in c-di-GMP levels in TMH-glu, TMH-gal, and TMH-rib, respectively. The $\Delta csrA::csrA$ strain exhibited c-di-GMP levels within ranges displayed by the WT strain. Therefore, biofilm and c-di-GMP production in TMH-gal and TMH-rib was highly dependent on functional CsrA. However, TMH-gal was selected for the next experiments to allow for comparison with published studies (47).

CsrA promotes translation of the *hmsT* mRNA. CsrA alters translation rates of mRNAs encoding enzymes for c-di-GMP synthesis or degradation, thereby altering c-di-GMP and EPS production in other bacteria (25, 35, 42, 43). Willis et al. (44) proposed that CsrA targets the *hmsP* and/or *hmsT* mRNAs to reduce c-di-GMP levels in the $\Delta csrA$ strain and identified putative CsrA binding sites in the 5' UTRs of these transcripts. Our experiments described above support this idea, since we showed reduced c-di-GMP levels in the $\Delta csrA$ strain.

To determine if translation of the *hmsP* and *hmsT* mRNAs are CsrA dependent, we constructed posttranscriptional green fluorescent protein (GFP) fusion reporters. The 5' UTR plus predicted CsrA binding motifs (44) were engineered in-frame to the coding sequence (CDS) of *gfpmut3.1* (Fig. 2A) and an inducible promoter, P_{tetO} . The use of the P_{tetO} promoter was intended to uncouple transcription from control by growth phases, environmental signals, or transcription factors. The 5' UTR of *flhDC* was used as a positive control because it is a validated target of CsrA in *Y. pseudotuberculosis* (48) and shares 100% nucleotide identity with the 5' UTR of *Y. pestis flhDC* mRNA. CsrA is identical between *Y. pestis* and *Y. pseudotuberculosis*; thus, *Y. pestis* CsrA was expected to bind the *flhDC* transcript. The 5' UTR of housekeeping gene *gyrB* that lacks CsrA binding motifs was used as a negative control.

GFP reporter fusion constructs were transformed into the WT and $\Delta csrA$ strains. Strains were grown in TMH-gal and fluorescence recorded at 3 h postinduction, when the greatest GFP induction was achieved for each construct (data not shown). As expected, GFP expression between the WT and $\Delta csrA$ strains from the *gyrB-gfp* reporter was comparable but was significantly reduced in the $\Delta csrA$ strain with the *flhDC-gfp* reporter (Fig. 2B). No significant difference in GFP expression between the WT and $\Delta csrA$




FIG 1 CsrA is required for EPS production and c-di-GMP synthesis. (A) Congo red (CR) binding assays were used to quantify EPS production of strains cultured in HIB or TMH supplemented with 0.2% of glucose (TMH-glu), galactose (TMH-gal), or ribose (TMH-rib). Error bars represent the means \pm standard errors of the means (SEM) of bound CR samples from 3 to 6 independent experiments. (B) C-di-GMP was extracted from strains grown in TMH-glu, TMH-gal, or TMH-rib. Means of two independent experiments are shown. Statistical significance was determined using one-way analysis of variance (ANOVA) with Dunnett's multiple comparisons posttest for each medium type (black lines) or to compare the WT strain across media (gray lines) (*, $P < 0.05$; ***, $P, 0.0005$; ****, $P < 0.0001$; n.s., not significant).

strains was noted for the *hmsP-gfp* reporter. However, significant reduction in GFP expression occurred in the *hmsT-gfp* reporter in the Δ *csrA* strain compared to the WT strain, suggesting that the *hmsT* mRNA translation was CsrA dependent.

Next, to determine if decreased *hmsT* mRNA translational levels in the Δ *csrA* strain are a result of decreased *hmsT* mRNA levels, we evaluated steady-state levels of the *hmsT* mRNA in the WT and Δ *csrA* strains using reverse transcription-quantitative PCR (RT-qPCR). We included an evaluation of the *hmsP* mRNA as a negative control, as *hmsP* mRNA translational levels were unaffected by CsrA. The relative steady-state mRNA levels of the *hmsT* mRNA were significantly lower in the Δ *csrA* strain than the WT strain, while the *hmsP* mRNA levels were similar between these strains (Fig. 2C). These data suggested that *hmsT* mRNA abundance was CsrA dependent.




FIG 2 CsrA does not directly regulate *hmsT* mRNA translation. (A) Schematic of the inducible GFP fusion reporters in which the native upstream untranslated sequences and the first 9 or 10 codons of *gyrB* (negative control), *flhDC* (positive control), *hmsP*, and *hmsT* were fused in frame to *gfpmut3.1* (*gfp*) and the anhydrotetracycline (ATC)-inducible promoter P_{tetO} in the WT and $\Delta csrA$ strains. (B) Posttranscriptional fusion reporter strains grown in TMH-gal to log phase were induced with ATc. At 3 h postinduction, the relative fluorescent units (RFU) and OD₆₀₀ were measured. Uninduced RFU/OD₆₀₀ values were subtracted from induced RFU/OD₆₀₀ values to compare between strains. Error bars represent means \pm SEM from three independent experiments. Statistical significance was determined by an unpaired *t* test (*, $P < 0.05$; n.s., not significant). (C) Steady-state transcript levels of *hmsP* and *hmsT* were compared between the WT and $\Delta csrA$ strains. Means \pm SD from two independent experiments are shown. Statistical significance was determined with a Student's *t* test (*, $P < 0.05$; n.s., not significant). For gel mobility shift assays, 0.8 nM 3'biotin end-labeled *hns* (negative control) (D), *flhDC* (positive control) (E), or *hmsT* (F) probes were incubated with increasing concentrations of purified CsrA-His₆. Kerafast biotinylated sRNA ladder (L), free (Fr), and bound (Bo) species are indicated. A broken line indicates migration of Fr labeled probe. One representative of two independent experiments is shown.

CsrA does not bind directly to the *hmsT* mRNA. To determine if CsrA regulation of the *hmsT* mRNA results from direct binding of CsrA, RNA electrophoretic mobility shift assays (REMSAs) were conducted. A transcript of the *hmsT* mRNA containing the same region as that in the *hmsT-gfp* reporter fusion was used to examine the interaction of the *hmsT* mRNA 5' UTR and CsrA. The *hns* mRNA that does not bind to CsrA was used as a negative control, and the 5' UTR of *flhDC* served as a positive control (48). As previously reported (48), the labeled *hns* probe did not shift with increasing concentrations of CsrA-His₆ (Fig. 2D). As expected, a shift occurred for the labeled *flhDC* probe at increasing concentrations of CsrA-His₆ (Fig. 2E). No shift was seen for the labeled *hmsT* probe with increasing concentrations of CsrA-His₆ (Fig. 2F), indicating that CsrA was not able to bind directly to the *hmsT* mRNA. These results strongly suggested that CsrA indirectly regulated *hmsT* mRNA translation.

CsrA binds specifically to the *hfq* mRNA. The mRNAs of known negative regulators of *hmsT*, RcsB or Hfq, may instead be targeted by CsrA. Indeed, CsrA orthologs of the plant pathogen *Erwinia amylovora* and *E. coli* repress mRNAs of *Y. pestis* orthologs of *rscB* (33) and *hfq* (49), respectively. Both *rscB* and *hfq* genes are part of polycistronic operons (33, 49–51). CsrA can target downstream genes within polycistronic operons by binding to CsrA binding motifs located in the 3' end of the upstream gene (52). Therefore, to determine if *Y. pestis* *rscB* and *hfq* mRNAs are candidate mRNA targets of




FIG 3 CsrA negatively regulates *hfq* mRNA translation. (A) Nucleotide sequence of the 3' end of the *miaA* gene (shaded gray) and the intercistronic region *miaA-hfq* genes plus ATG start of the *hfq* mRNA. The Shine-Dalgarno (SD) sequence and the ATG start codon for the *hfq* mRNA coding region are boldfaced and underlined. GGA motifs of the two putative CsrA binding sites are in red. The transcriptional start site (TSS) from the immediate upstream promoter is depicted by an arrow. (B) Posttranscriptional fusion reporter plasmids composing the upstream sequence and the first 9 codons of *hfq* fused to *gfpmut3.1* (*gfp*), and the P_{tetO} promoter was used in the WT and $\Delta csrA$ strains. Error bars represent mean \pm SEM relative RFU/OD₆₀₀ from four independent experiments.

CsrA, a position matrix scan (44) was applied to the 5' UTR of *rcsB* and *hfq* mRNAs to identify putative CsrA binding sites. Up to -250 bases upstream from the translational initiation codon were queried, in keeping with ranges for to-date validated CsrA targeted 5' UTRs (36, 53, 54). Two potential binding sites were found in the *hfq* transcript (Fig. 3A; see also Fig. S1 in the supplemental material); one overlapped the Shine-Dalgarno (SD) sequence of the *hfq* mRNA (BS1) and the other occurred in a stem-loop, spanning the -151 to -159 nucleotide sequence located at the 3' end of the upstream gene, *miaA* (BS2). The *rcsB* leader region contained no potential CsrA binding sites (data not shown). To experimentally test if *hfq* mRNA translation was CsrA dependent, we first generated an *hfq-gfp* posttranscriptional fusion reporter containing both putative CsrA binding sites. The GFP reporter expression from the *hfq-gfp* reporter in TMH-gal medium was compared between the WT and $\Delta csrA$ strains (Fig. 3B). Expression was significantly higher in the $\Delta csrA$ strain, suggesting that CsrA repressed *hfq* mRNA translation.

To determine if CsrA binds directly to the *hfq* mRNA, REMSAs were conducted. A minor shift in the labeled *hfq* probe was noted at 75 nM CsrA-His₆, but at 150 nM CsrA-His₆ the entire complex had shifted (Fig. 4A). Competitive binding assays verified that CsrA binding to the *hfq* mRNA was specific because, when competed with 2- and 10-fold excess unlabeled *hfq* probe, the labeled *hfq* probe shifted only partially or not at all, respectively (Fig. 4B).

To determine if CsrA binds to the identified GGA sites, we generated labeled probes with CC substitutions for the GG nucleotides in the GGA motif for BS1 (*hfq* BS1 mutant), CCC substitutions for the GGA motif at BS2 (*hfq* BS2 mutant) alone, and the respective aforementioned substitutions at both sites (*hfq* BS1/BS2 mutant). All mutant probes showed reduced binding to CsrA-His₆ but at varied levels (Fig. 4C to E). For the *hfq* BS1 mutant probe, a small effect on binding to CsrA-His₆ was noted by the presence of two complexes, one that had not shifted and the other that had shifted at ≥ 112 nM CsrA-His₆ (Fig. 4C). The *hfq* BS2 mutant probe (Fig. 4D) and *hfq* BS1/BS2 mutant probe




FIG 4 CsrA binds to two GGA binding sites in the 5' UTR of *hfq* mRNA. (A) 3' Biotin end-labeled *hfq* probe (0.8 nM) and increasing concentrations of purified CsrA-His₆ were coincubated. Kerafast biotinylated sRNA ladder (L), free (Fr), and bound (Bo) species are indicated. A broken line indicates migration of Fr labeled probe. (B) For mobility shift competition assays, labeled *hfq* probe was coincubated with unlabeled *hfq* probe at 2 (1.6 nM) or 10 (8 nM) times more than the labeled *hfq* probe and 112.5 nM CsrA-His₆. (C, D, and E) Binding site mutant mobility shift assays were performed as described for panel A, except the *hfq*-labeled probes contained a mutation at BS1 (C), BS2 (D), or BS1/BS2 (E). One representative of two independent experiments is shown.

(Fig. 4E) both exhibited a complete loss of binding to CsrA-His₆, because no shift was noted. *Y. pestis* *hfq* mRNA can also be transcribed from a promoter immediately upstream of its translational start codon. In this case, the *hfq* transcript composes a 90-nucleotide 5' UTR sequence with only BS1 present (50). Additionally, a shorter GFP reporter fusion construct representative of this shorter 5' UTR (−115 through +27 nucleotides in relation to the ATG start) had increased GFP expression in the Δ *csrA* strain compared to that of the WT strain (Fig. S2). Thus, BS1 and BS2 are authentic CsrA binding sites.

CsrA blocks translation but does not accelerate the decay rate of the *hfq* mRNA.

CsrA may decrease *hfq* mRNA translation by accelerating its decay rate, blocking its translation by preventing ribosome binding, or by facilitating premature transcription termination (55). To test if CsrA alters stability of the *hfq* mRNA, we determined the half-life of this transcript in the WT and Δ *csrA* strains after addition of rifampin to prevent transcription initiation. The mean (\pm standard deviation [SD]) half-life of the *hfq* mRNA (Fig. 5A) was similar between the WT (12 ± 2.0 min) and Δ *csrA* (11.3 ± 1.3 min) strains. Therefore, CsrA binding does not destabilize the *hfq* mRNA.

To determine if *hfq* mRNA translational repression results from CsrA binding and preventing translation, we performed *in vitro* cell-free translational assays. We initially utilized an mRNA template containing the full-length sequence of the *hfq* gene engineered with a Flag tag preceding the stop codon. However, similar to a previous report using a full-length *E. coli* *hfq* gene template in cell-free translational assays (49), multiple bands were observed on immunoblots due to incomplete denaturation of the hexameric Hfq protein. Hence, mRNA templates derived from the *hfq-gfp* and *hmsT-gfp* (negative control) reporters described above were used. Similar amounts of the HmsT-GFP protein were synthesized in the presence and absence of CsrA (Fig. 5B), as expected if CsrA did not directly bind and alter translational levels of the HmsT mRNA. However, translation of the *hfq-gfp* transcript was inhibited in the presence of CsrA (Fig. 5B), as reflected by the 2.5 (\pm SD, 0.67) greater levels of Hfq-GFP protein in the absence of CsrA relative to its presence. This outcome supported that CsrA binds directly to and prevents translation of the *hfq* mRNA.

CsrA represses *hfq* mRNA translation, facilitating derepression of *hmsT* mRNA translation. *Y. pestis* Hfq posttranscriptionally represses *hmsT* mRNA translation by accelerating its decay rate (22, 23). Therefore, the *hmsT* mRNA half-life should be shorter in a Δ *csrA* strain if CsrA no longer represses the *hfq* mRNA. To determine the mRNA stability of the *hmsT* mRNA in the Δ *csrA* strain versus the WT strain, we determined the half-life of the *hmsT* mRNA as described above. As predicted, the mean \pm




FIG 5 mRNA stability and translation of the *hfq* mRNA. (A) The WT and $\Delta csrA$ strains were grown to log phase in TMH-gal, and RNA was isolated from samples taken at 0 min (prerifampin) and after the addition of 400 $\mu\text{g/ml}$ rifampin. Relative *hfq* mRNA levels remaining at the indicated time points were quantified using RT-qPCR. The amount of *hfq* mRNA in each strain at 0 min relative to rifampin addition was set to 100%. The percent mRNA remaining thereafter was plotted versus time as semilogarithmic graphs. The mean \pm SEM percent mRNA from four independent experiments is shown. (B) *In vitro* translational assays were performed with the PURExpress kit using translational fusions transcripts of *hfq-gfp* and *hmsT-gfp* (negative control) expressed from a T7 promoter. The mean \pm SD fold change in HmsT-GFP and Hfq-GFP signal between samples in the presence or absence of CsrA was derived from three technical replicates of the immunodot blot. One representative dot blot is shown.

SD half-life of the *hmsT* mRNA (Fig. 6A) was reduced by 27.8% in the $\Delta csrA$ strain (2.6 ± 0.0 min) compared to the WT strain (3.6 ± 0.3 min).

We reasoned further that if CsrA represses *hfq* mRNA translation to facilitate derepression of *hmsT* mRNA translation, then a $\Delta csrA \Delta hfq$ strain should show reestablishment of *hmsT* mRNA levels and increased biofilm production. To determine if this occurs, we generated a $\Delta csrA \Delta hfq$ double mutant strain. A complemented derivative thereof, $\Delta csrA \Delta hfq$ (pLG*hfq*) strain, was also constructed by inserting the *hfq* gene and native promoter sequence on a low-copy-number plasmid, pLG338, to create pLG*hfq*. First, steady-state levels of the *hmsT* mRNA at log phase were evaluated in the $\Delta csrA \Delta hfq$ and $\Delta csrA \Delta hfq$ (pLG*hfq*) strains compared to the $\Delta csrA$ and WT strains in TMH-gal (Fig. 6B). As hypothesized, the $\Delta csrA \Delta hfq$ strain exhibited restored levels of the *hmsT* mRNA comparable to the WT strain. Additionally, the $\Delta csrA \Delta hfq$ (pLG*hfq*) complemented strain showed *hmsT* levels comparable to the $\Delta csrA$ strain and significantly lower than that of the WT strain.

During routine lab culture, *Y. pestis* incurs spontaneous loss of a 102-kb locus, referred to as the pigmentation locus (56), or Pgm locus, named for the ability to form pigmented colonies on CR-supplemented agar (57). The *hmsHFRS* operon is located within the *pgm* locus and confers this phenotype. When culturing our $\Delta csrA \Delta hfq$ strain on media that promote high biofilm production, we noted that the strain had a high propensity to form nonpigmented colonies, reflecting loss of EPS production. Therefore, to quantify EPS levels in these strains, CR assays were performed using LB medium that does not support high levels of biofilm production. Nonetheless, EPS levels in the $\Delta csrA \Delta hfq$ strain were not different from those of the WT strain (Fig. 6C), and the $\Delta csrA \Delta hfq$ (pLG*hfq*) complemented strain showed EPS levels comparable to those




FIG 6 Epistasis analysis confirms that CsrA indirectly derepresses *hmsT* mRNA translation by targeting the *hfq* mRNA. (A) *hmsT* mRNA stability was determined as described for Fig. 5A. (B) Steady-state transcript levels of *hmsT* were compared between the WT (same as Fig. 2C), $\Delta csrA$ (same as Fig. 2C), $\Delta csrA \Delta hfq$, and complemented $\Delta csrA \Delta hfq$ (pLGhfq) strains. Means \pm SD from two independent experiments are shown. (C) Congo red (CR) binding assays were used to quantify EPS production in strains cultured in LB medium. A representative picture of strains grown for 48 h on LB containing CR is shown below. Error bars represent the mean \pm SD bound CR from two independent experiments. Statistical significance was determined using one-way ANOVA with a Dunnett's multiple-comparison posttest (**, $P < 0.01$; ***, $P = 0.0005$; n.s., not significant).

of the $\Delta csrA$ strain but significantly lower than that of the WT strain (Fig. 6C). Additionally, we analyzed the pigmentation phenotypes of the strains on LB agar supplemented with CR. Pigmentation phenotypes matched the quantitative CR binding assay data. Thus, as hypothesized, EPS and *hmsT* mRNA steady-state levels in the $\Delta csrA \Delta hfq$ strain and $\Delta csrA \Delta hfq$ (pLGhfq) complemented strain corresponded with that of the WT and $\Delta csrA$ strains, respectively.

CsrA is required for the robust formation of biofilm-mediated blockage in fleas.

Finally, to define the role of CsrA in biofilm-mediated flea foregut blockage, we compared cumulative blockage rates in cohorts of rat fleas infected with WT, $\Delta csrA$, and $\Delta csrA::csrA$ strains over a 28-day period (Fig. 7A). Fleas infected with the $\Delta csrA$ strain achieved significantly lower cumulative blockage rates of 16.8% (\pm SD, 3.2) relative to the WT strain-infected fleas, which achieved rates of 39.8% (\pm SD, 10.4). Similar to the WT strain-infected fleas, the $\Delta csrA::csrA$ strain-infected fleas exhibited rates of 34.2% (\pm SD, 11.7). An analysis of temporal incidence of blockage showed that while fleas infected with the WT and the $\Delta csrA::csrA$ strains attained peak blockage incidence at \sim 15 days postinfection (dpi), the $\Delta csrA$ strain-infected fleas exhibited generally low blockage incidence, which was significant at 15 and 19 dpi (Fig. 7B). Flea bacterial loads and flea infection rates were not significantly different among the strains (Fig. 7C and D) despite being slightly lower in the $\Delta csrA$ -infected fleas. Therefore, growth kinetics of the $\Delta csrA$ strain in fleas was likely slightly lower, similar to that reported during *in vitro* growth (44). CsrA mutants in other bacterial species also show slow growth kinetics (28, 58). Additionally, the bacterial loads and infection rates of the $\Delta csrA$ strain resembled those reported for biofilm-deficient *Y. pestis* strains (7, 59–61). Biofilm is thought to maintain bacteria in aggregates that are not easily cleared through defecation after flea blood-feeding and digestion (reviewed in reference 3), accounting for lower bacterial number in strains with reduced biofilm levels.

DISCUSSION

Our work provides evidence for CsrA control of biofilm production in *Y. pestis* occurring through a tiered posttranscriptional regulatory mechanism (Fig. 8). In summary, cues from alternative carbon catabolism are transduced by CsrA to repress *hfq* mRNA




FIG 7 Flea foregut blockage and infection dynamics of the $\Delta csrA$ strain. Cohorts of *Xenopsylla cheopis* fleas were artificially infected with the WT (black), $\Delta csrA$ (red), or $\Delta csrA::csrA$ (gray) strains and monitored for blockage over 28 days postinfection (dpi). (A) Cumulative flea blockage rate of each strain is shown for 100 fleas (50 male, 50 female), with error bars representing the means \pm SEM from three independent experiments. One-way ANOVA with Holm Sidak's multiple-comparison posttest was used to determine statistical significance (*, $P < 0.05$; n.s., not significant). (B) Number of fleas blocked on 5, 8, 12, 15, 19, 22, and 26 dpi for each strain is shown as means \pm SEM for three independent experiments. Two-way ANOVA with Holm Sidak's multiple-comparison posttest was used to determine statistical significance for each time point (**, $P < 0.01$; ****, $P < 0.0001$). (C) Mean number of CFU per flea ($n = 10$ to 20) at 0, 7, and 28 dpi. Error bars represent means \pm SEM from 2 to 3 independent experiments. Two-way ANOVA was used to test for statistical significance (n.s., not significant). (D) Percentage of fleas infected ($n = 10$ to 20) at 0, 7, and 28 dpi. Error bars represent means \pm SEM from 2 to 3 independent experiments. Two-way ANOVA was used to test for statistical significance (n.s., not significant).

translation, which, in turn, leads to translational derepression of the *hmsT* mRNA and a respective increase in intracellular c-di-GMP pools and biofilm production. Thus, CsrA is required to facilitate robust *Y. pestis* biofilm-mediated foregut blockage rates in rat fleas. Maintenance of normal blockage rates drives epizootic-scale plague transmission events (2, 62). Thus, an $\sim 50\%$ reduction in blockage rate, as seen for the *csrA* mutant, is synonymous with a compromised ability to maintain natural plague transmission cycles. Coincidentally, an *hmsT* mutant exhibits a similar $\sim 50\%$ decrease in blockage rate (20, 21), in agreement with the notion that *csrA* mutant blockage rates are due to the absence of CsrA-dependent enhancement of *hmsT* mRNA translation.

Using ribose- and galactose-supplemented media enabled our reiteration that *Y. pestis* EPS levels are significantly greater during culture on alternative rather than primary carbon sources (44, 63). This aligns with observations that metabolic genes involved in uptake of alternative sugars, particularly pentose sugars, are strongly induced in blocked fleas (4, 5), and an intact pentose phosphate pathway is required for efficient flea foregut blockage (61). In addition, we demonstrated that severe impairment in EPS levels in the *csrA* mutant resulted from exacerbated defects in producing c-di-GMP on alternative carbon sources. CsrA is therefore critical for stimulating c-di-GMP synthesis to increase EPS levels coincident with alternative carbon metabolism. Improved growth and biofilm production on alternative carbon sources in *Y. pestis* is mediated by cyclic AMP (cAMP) and the cAMP receptor protein complex, cAMP-CRP, under glucose-limiting conditions (44, 63). Thus, *Y. pestis* CsrA-dependent biofilm formation overlaps carbon catabolite repression enabling biofilm production. Interestingly, in *Y. pseudotuberculosis*, cAMP-CRP activates *csrC* but




FIG 8 Current model for the CsrA-dependent regulation of c-di-GMP synthesis and biofilm formation in *Y. pestis*. In *Y. pestis*, the HmsHFRS proteins synthesize and export EPS to outside the cell to propagate biofilm formation, which leads to biofilm-mediated blockage in fleas. CsrA transduces alternative carbon metabolism cues to enhance biofilm EPS production (green thick broken arrow). CsrA does this through indirect positive regulation of the c-di-GMP synthesis enzyme, HmsT. Hfq represses *hmsT* mRNA translation by promoting its mRNA decay, but CsrA binds to two binding sites in the 5'UTR of *hfq* to inhibit its translation (solid red line), thereby alleviating repression of the *hmsT* mRNA translation by Hfq. How and under which physiological conditions ncRNAs CsrB and CsrC antagonize CsrA activity (solid blue line) in *Y. pestis* are yet to be determined.

represses *csrB* transcription, thereby optimizing infection fitness to the nutritional status of the mammalian host (64). CsrB also negatively regulates *Y. pseudotuberculosis* HmsHFRS-dependent biofilms (65). In *E. coli*, cAMP-CRP interfaces with the Csr system by inhibiting *csrC* and *csrB* expression and promoting CsrA-dependent biofilm inhibition (41, 66). If and how *Y. pestis* orthologs of sensory ncRNAs CsrB and CsrC (67) contribute to finely adjust CsrA activity in response to physiological changes during flea infection is under our investigation currently.

Bellows et al. (22) described that the *hmsT* mRNA is posttranscriptionally repressed by Hfq binding to its 5' UTR, leading to accelerated transcript decay and decreases in transcript abundance of the *hmsT* mRNA. Hfq also posttranscriptionally regulates the *hmsT* mRNA through its AU-rich, long 3' UTR sequence (23). A yet-to-be-identified small ncRNA is predicted to facilitate Hfq-*hmsT* mRNA interactions (22, 23). Consistent with these reports, we demonstrated that CsrA directly repressed *hfq* mRNA translation and that the *hmsT* mRNA incurred accelerated transcript decay. Epistatic analysis using a *csrA hfq* double mutant, in which we observed a restoration of *hmsT* mRNA and EPS levels to that exhibited by the wild-type strain, reinforced our findings. Notably, the *csrA hfq* double mutant exhibited slow growth kinetics relative to the other strains particularly when the Pgm locus was retained. However, when the Pgm locus was lost, the strain grew relatively faster (data not shown), suggesting that high biofilm production compromises growth fitness. Thus, CsrA in *Y. pestis* may play a role in optimizing growth fitness under nutritional conditions that promote costly biofilm production.

Hfq indirectly activates transcription of *hmsP*, and, together with posttranscriptional repression of the *hmsT* mRNA, causes decreases in biofilm and c-di-GMP levels in *Y. pestis* cultured on brain-heart infusion medium (22). However, in TMH-gal we noted that in an *hfq* mutant strain, the mRNA levels of *hmsT* were significantly greater than that of the wild-type strain, as expected, whereas *hmsP* transcript levels were similar

between the wild-type and *hfq* mutant strains (see Fig. S3 in the supplemental material). We also showed that CsrA does not affect *hmsP* mRNA steady-state or translational levels, thereby eliminating a role for CsrA-dependent regulation of the *hmsP* mRNA in biofilm formation under biologically relevant conditions.

In *E. coli* MG1655, CsrA facilitates repression of an *hfq* mRNA originating from a promoter immediately upstream of the *hfq* ATG start through occlusion of ribosome binding and not accelerated mRNA decay (49). Coincidentally, the CsrA binding site at the Shine-Dalgarno site for *hfq* is identical between *Y. pestis* and *E. coli* (Fig. S4). However, unlike *Y. pestis*, *E. coli* MG1655 does not similarly encode other GGA motifs upstream of the *hfq* mRNA translational start codon (Fig. S4). In *Y. pestis*, *hfq* mRNA transcribed with the upstream *miaA* gene fully restores Hfq function to an *hfq* mutant (50), emphasizing the significance of this transcript for production of functional Hfq levels. CsrA repression of this *miaA-hfq*-containing transcript in *Y. pestis* likely transpires through the two CsrA binding sites or the binding site at the Shine-Dalgarno site when the *hfq* transcript is derived from the immediately upstream promoter. In this way, *hfq* mRNA translation is expected to be more robustly inhibited by CsrA. Furthermore, the *Y. pestis* *hfq* transcript mutated only at the Shine-Dalgarno site possessed only a minor inability to completely shift (Fig. 3C). This may reflect an insufficiency of this binding site to properly repress *hfq* translation of the *miaA-hfq*-containing transcript, hence the need for the second binding site.

In numerous pathogens, Hfq is critical for mammalian virulence (68, 69), and in *Y. pestis* it is also essential for flea foregut blockage (47). Hfq regulates distinct ncRNA repertoires required for physiological fitness that are conditionally expressed during changing infection stages (68, 69). The highly stable nature of the *hfq* mRNA and repression of *hfq* mRNA translation without mRNA decay revealed by our half-life studies conceivably preserves *hfq* mRNA levels for any future critical rapid redeployment of Hfq protein. CsrA-mediated alterations in the *hfq* mRNA chiefly occurred when the number of blocked rat fleas seen was at its peak. Whether, during this peak blockage stage, (i) the ncRNA that facilitates the Hfq-*hmsT* mRNA interaction is produced, requiring CsrA repression of the *hfq* mRNA and (ii) ncRNAs CsrB and CsrC are not expressed to prevent sequestration of CsrA are intriguing questions.

CsrA-dependent biofilm regulation can occur through multiple mechanisms in bacteria. For example, in *E. coli*, CsrA represses translation of mRNAs encoding DGCs (25), PgaABCD, a homolog to HmsHFRS (36), and the NhaR transcriptional regulator that activates *pgaABCD* transcription (70) but promotes translation of the *ymdA* mRNA involved in inhibiting biofilm production (54). Similarly, we predict that CsrA targets other mRNAs involved in biofilm formation in *Y. pestis*. One putative *Y. pestis* target that encodes a CsrA GGA binding motif in its 5' UTR is the *hmsHFRS* mRNA (44). Future studies will be needed to validate putative mRNA targets in *Y. pestis*. Nonetheless, indirect modulation of DGC mRNAs to promote biofilm production, as illustrated here for CsrA in *Y. pestis*, is seldom appreciated as part of the repertoire of CsrA-mediated molecular mechanisms of biofilm control. Notably, this contrasts with the better-known paradigmatic role of CsrA direct translational repression of DGC mRNAs to inhibit biofilm formation in other Gammaproteobacteria.

MATERIALS AND METHODS

Bacterial strains, plasmids, and growth conditions. Bacterial strains and plasmids used in this study are listed in Table S1 in the supplemental material. The *Y. pestis* KIM6+ (pCD1⁻) strains were cultured on Congo red-heart infusion agar (57) to confirm the presence of the *hmsHFRS* locus prior to subsequent culturing. Strains were grown at 25°C with shaking unless otherwise stated. The chemically defined TMH medium was prepared as described previously (46). DNA sequencing verified all constructs.

Construction of *Y. pestis* mutant and complemented strains. Primers are listed in Table S2 under "Mutant and complementation strain construction." To generate the *Y. pestis* Δ *csrA*::*csrA* complemented *csrA* mutant strain, the *csrA* gene, with flanking promoter, and terminator regions were cloned into pUC18R6KT-mini-Tn7T-Km (71) at the EcoRI sites to create pUC18R6KT-mini-Tn7T-Km-*csrA*. This plasmid was then used to transpose the *csrA* expression fragment into the *gImS-pstS* site of the previously generated *csrA* mutant strain (44) as previously described (71).

To create the $\Delta csrA \Delta hfq$ mutant strain, the *hfq* gene in the *csrA* mutant strain was replaced by a kanamycin resistance cassette by homologous recombination, as reported in a previous study (47). This was done by PCR amplification of a fragment containing flanking regions of the *hfq* gene and kanamycin cassette from the *hfq* mutant (47) genomic DNA using *hfq* deletion primers (Table S2). The *hfq* gene and its up- and downstream sequences were PCR amplified (Table S2) and cloned into a low-copy-number vector, pLG338 (72), at the *Sma*I site to create plasmid pLG*hfq*. The $\Delta csrA \Delta hfq$ strain was transformed with pLG*hfq* to generate the $\Delta csrA \Delta hfq$ (pLG*hfq*) complemented strain.

CR binding assay. CR binding assays were performed as previously described, with minor modifications (17). CR was used at final concentrations of 0.03 ng/ml (HIB), 0.06 ng/ml (TMH-glu), 0.12 ng/ml (TMH-gal or TMH-rib), or 0.02 ng/ml (LB) to account for EPS production and incubated for 3 h (HIB and LB) or 1 h (TMH). The A_{500} values of sample supernatants were subtracted from medium controls containing CR at their respective concentrations to calculate relative bound CR. The value for the WT strain under each condition was set to 1 for Fig. 1. These values then were multiplied by either 0.5, 1, or 4 for HIB, TMH-glu, and TMH-gal/rib to correct for the amount of CR added per medium condition.

C-di-GMP extraction and quantification. Strains were grown to late log phase. C-di-GMP was extracted from pelleted cells with extraction buffer (100 μ l/48-mg cell pellet), and samples were neutralized and quantified using high-performance liquid chromatography (HPLC) as described previously (16, 18, 22).

Fusion reporter construction and assay. The upstream sequences and partial coding sequences were PCR amplified (primers are listed in Table S2 under “Translational fusion reporters”) for *flhDC*, *gyrB*, *hmsP*, *hmsT*, and *hfq*. The generated fragments were then fused to amplified fragments of *gfpmut3.1* from pFU34 (73) by splice overlap extension PCR (SOE-PCR) and then subjected to digestion with *Eco*RI and cloned into low-copy-number plasmid pMWO78 (74) at the *Eco*RI/*Sma*I sites. Plasmids generated were denoted pMWO78::5’UTR of interest-*gfpmut3.1* and transformed into the WT and $\Delta csrA$ strains (Table S1).

GFP reporter strains were grown to early log phase, split into separate flasks, and treated with anhydrotetracycline (ATc; 200 ng/ml) or vehicle. At 3 h postinduction, the numbers of relative fluorescent units (RFU; excitation, 475 nm; emission, 515 nm) were measured on a TECAN Spark plate reader with optical density at 600 nm (OD_{600}) values taken simultaneously. The medium blank RFU reading was subtracted from the culture RFU of samples and normalized to OD_{600} values to account for bacterial growth. The difference of RFU/ OD_{600} values of induced samples from uninduced samples then was calculated.

CsrA-His₆ expression and purification. The *csrA* gene was amplified (primers listed in Table S2 under “CsrA-his tag construct”), digested with *Nco*I/*Xho*I, and cloned into matching sites in pET28A (Novagen) to generate pET28::*csrA-his₆*, which was transformed into the *E. coli* strain, B121 λ DE3 pLysS. Cultures were induced as previously described (75). Cell pellets were resuspended in protein buffer (100 mM Tris-HCl, 300 mM NaCl, pH 7.5, 20 mM imidazole), 26 U/ml Benzonase (Sigma), and one tablet of cOmplete Mini EDTA-free protease inhibitor cocktail (Roche) per 10 ml buffer and then lysed by sonication. Protein was purified from the supernatant using affinity chromatography as previously described (75). Relevant fractions were dialyzed with a 10,000 molecular weight cutoff (MWCO) Slide-A-Lyzer G2 dialysis cassette (Thermo Fisher Scientific) in dialysis buffer (protein buffer without imidazole). Buffer exchange was performed with 100 mM Tris-HCl, pH 7.5, using a Pall Microsep centrifugal device (3,000 MWCO). Concentrated protein was quantified using the DC protein assay (Bio-Rad). Before incubation with RNA probe, CsrA-His₆ was prepared using 10 mM Tris-HCl, 10% glycerol, pH 7.5. CsrA protein was diluted as previously described (76).

Construction of *hfq* mRNA probes with GGA site mutations. The nucleotide fragment containing a T7 promoter, the upstream region of *hfq* (bp –177 through 74), and the GG-to-CC mutation in BS1 was commercially synthesized (Eurofins) and blunt-end cloned into pJet1.2 (Thermo Fisher Scientific) to create pJet1.2::*hfq* UTR BS1mut. To generate the BS2 and BS1/BS2 fragments, primers (Table S2 under “EMSA probes”) containing the GGA-to-CCC mutation in BS2 or CC-to-GG restoration in BS1 were used with inverse PCR of the pJet1.2::*hfq* UTR BS1mut to generate mutated fragments for labeled probe generation.

REMSA. To generate biotin-labeled EMSA probes, PCR fragments were first generated from primers (Table S2 under “EMSA probes”) where each forward primer contained a T7 promoter sequence. Fragments were gel purified and transcribed with the MegaShortScript T7 transcription kit (Invitrogen). Probes were purified using the RNA Clean and Concentrator-25 kit (Zymo) and their size confirmed by electrophoresis. RNA probes were then labeled using a Pierce RNA 3’-end biotinylation kit and purified with the Oligo Clean and Concentrator kit (Zymo). Labeled RNA concentrations were determined using a Thermo Scientific NanoDrop.

CsrA-His₆ probe binding reactions were conducted in 10 \times CsrA binding buffer (76) and incubated at 37°C for 30 min. For REMSAs shown in Fig. 4, binding reaction mixtures included 60 ng unlabeled yeast RNA (Invitrogen) and SUPERase-In (Invitrogen). CsrA-His₆-probe complexes were electrophoresed on a 6% nondenaturing polyacrylamide gel, transblotted to a positively charged nylon membrane, and then UV cross-linked (120 mJ/cm²). Biotinylated probes were detected using the chemiluminescent nucleic acid detection module (Thermo Fisher Scientific).

In vitro cell-free translation assay. The PURExpress kit (New England Biolabs) was used per the manufacturer’s instructions. The reporter fusion constructs pMWO78::*hfq-gfpmut3.1* or pMWO78::*hmsT-gfpmut3.1*, described above, were used as templates to generate *hfq-gfp* and *hmsT-gfp* mRNA transcripts with primers containing a T7 promoter sequence (Table S2 under “EMSA probes”) using the MegaShortScript T7 transcription kit. mRNA transcripts were purified with the RNA Clean and Concentrator-25 kit (Zymo). Reaction mixtures contained 326 nM mRNA transcript with 6.2 μ M CsrA-His₆.

and were incubated at 37°C. GFP signal was detected by immunoblot using 1:20,000 rabbit anti-GFP (Invitrogen), 1:100,000 goat anti-rabbit horseradish peroxidase (Invitrogen), and the SuperSignal West Femto kit (Thermo Fisher Scientific) and quantified by densitometry on a ChemicDoc MP using Image Lab 4.1.

Quantification of steady-state mRNA levels and mRNA stability assays. Samples were added to RNeasy Protect bacterial reagent (Qiagen). RNA isolation, qRT-PCR (Table S2 under "RT-qPCR"), and $2^{-\Delta\Delta CT}$ analysis was conducted as previously described (77). For steady-state mRNA analysis, samples were collected from strains grown to log phase. For mRNA stability assays, rifampin (400 $\mu\text{g}/\text{ml}$) was added to strains grown to log phase. To quantify *hfq* mRNA half-life, samples were collected at 0 (prerifampin) and 3, 6, 9, 12, and 15 min postrifampin. To quantify *hmsT* mRNA half-life, samples were collected at 0 (prerifampin) and 2, 3, 4, 5, 6, 7, and 8 min postrifampin addition. Percent mRNA remaining relative to $t=0$ (set to 100%) was plotted on semilog graphs.

Flea infections. Cohorts of *Xenopsylla cheopis* fleas were artificially infected with *Y. pestis* strains, and infected flea maintenance, blockage, and CFU enumeration were performed as previously described (21, 78). To account for growth defects in the ΔcsrA strain, strains were grown overnight at room temperature and then moved to 37°C at 5 h prior to infection. Studies with mice were performed in strict accordance with the U.S. National Institutes of Health (NIH) *Guide for the Care and Use of Laboratory Animals* (79) and as approved by the Washington State University Institutional Animal Care and Use Committee.

Statistical analysis. Details of statistical analysis using GraphPad Prism version 8.1.1 are provided in the legends of Fig. 1 to 7.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 2.1 MB.

FIG S2, TIF file, 0.3 MB.

FIG S3, TIF file, 0.3 MB.

FIG S4, TIF file, 1.1 MB.

TABLE S1, DOCX file, 0.02 MB.

TABLE S2, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS

We thank Athena Lemon and Haiqin Yan for technical assistance, Vladimir Motin for the ΔcsrA strain, and Virginia Miller for the pMWO plasmid. We are indebted to Alex Bobrov, Olga Kirillina, and Petra Dersch for experimental advice. Thanks also to Bob Perry, Anders Omsland, and Haiqin Yan for constructive feedback.

This study was funded by the National Institutes of Health grants R01AI117016-01A1 to V.V. and R01GM109259 to C.W.

REFERENCES

- Perry RD, Fetherston JD. 1997. *Yersinia pestis*—etiologic agent of plague. *Clin Microbiol Rev* 10:35–66. <https://doi.org/10.1128/CMR.10.1.35>.
- Hinnebusch BJ, Bland DM, Bosio CF, Jarrett CO. 2017. Comparative ability of *Oropsylla montana* and *Xenopsylla cheopis* fleas to transmit *Yersinia pestis* by two different mechanisms. *PLoS Negl Trop Dis* 11:e0005276. <https://doi.org/10.1371/journal.pntd.0005276>.
- Hinnebusch BJ, Jarrett CO, Bland DM. 2017. Fleaing the plague: adaptations of *Yersinia pestis* to its insect vector that lead to transmission. *Annu Rev Microbiol* 71:215–232. <https://doi.org/10.1146/annurev-micro-090816-093521>.
- Vadyvaloo V, Jarrett C, Sturdevant DE, Sebbane F, Hinnebusch BJ. 2010. Transit through the flea vector induces a pretransmission innate immunity resistance phenotype in *Yersinia pestis*. *PLoS Pathog* 6:e1000783. <https://doi.org/10.1371/journal.ppat.1000783>.
- Vadyvaloo V, Jarrett C, Sturdevant D, Sebbane F, Hinnebusch BJ. 2007. Analysis of *Yersinia pestis* gene expression in the flea vector. *Adv Exp Med Biol* 603:192–200. https://doi.org/10.1007/978-0-387-72124-8_16.
- Bacot AW, Martin SCJ. 1914. Observations on the mechanism of the transmission of plague by fleas. *J Hyg* 13:423–439.
- Hinnebusch BJ, Perry RD, Schwan TG. 1996. Role of the *Yersinia pestis* hemin storage (*hms*) locus in the transmission of plague by fleas. *Science* 273:367–370. <https://doi.org/10.1126/science.273.5273.367>.
- Perry RD, Pendrak ML, Schuetz P. 1990. Identification and cloning of a hemin storage locus involved in the pigmentation phenotype of *Yersinia pestis*. *J Bacteriol* 172:5929–5937. <https://doi.org/10.1128/jb.172.10.5929-5937.1990>.
- Perry RD, Bobrov AG. 2010. Role of cyclic di-GMP in biofilm development and signaling in *Yersinia pestis*, p 270–281. In Wolfe AJ, Visick KL (ed), *The second messenger cyclic di-GMP*. ASM Press, Washington, DC. <https://doi.org/10.1128/9781555816667>.
- Perry RD, Bobrov AG, Kirillina O, Jones HA, Pedersen L, Abney J, Fetherston JD. 2004. Temperature regulation of the hemin storage (*Hms+*) phenotype of *Yersinia pestis* is posttranscriptional. *J Bacteriol* 186:1638–1647. <https://doi.org/10.1128/JB.186.6.1638-1647.2004>.
- Jenal U, Reinders A, Lori C. 2017. Cyclic di-GMP: second messenger extraordinaire. *Nat Rev Microbiol* 15:271–284. <https://doi.org/10.1038/nrmicro.2016.190>.
- Ryan RP. 2013. Cyclic di-GMP signalling and the regulation of bacterial virulence. *Microbiology* 159:1286–1297. <https://doi.org/10.1099/mic.0.068189-0>.
- Valentini M, Filloux A. 2016. Biofilms and cyclic di-GMP (c-di-GMP) signaling: lessons from *Pseudomonas aeruginosa* and other bacteria. *J Biol Chem* 291:12547–12555. <https://doi.org/10.1074/jbc.R115.711507>.
- Sun YC, Jarrett CO, Bosio CF, Hinnebusch BJ. 2014. Retracing the evolutionary path that led to flea-borne transmission of *Yersinia pestis*. *Cell Host Microbe* 15:578–586. <https://doi.org/10.1016/j.chom.2014.04.003>.
- Hinnebusch BJ, Chouikha I, Sun YC. 2016. Ecological opportunity, evolution, and the emergence of flea-borne plague. *Infect Immun* 84:1932–1940. <https://doi.org/10.1128/IAI.00188-16>.
- Bobrov AG, Kirillina O, Vadyvaloo V, Koestler BJ, Hinz AK, Mack D, Waters CM, Perry RD. 2015. The *Yersinia pestis* *HmsCDE* regulatory system is essential for blockage of the oriental rat flea (*Xenopsylla cheopis*), a classic

54. Renda A, Poly S, Lai YJ, Pannuri A, Yakhnin H, Potts AH, Bevilacqua PC, Romeo T, Babitzke P. 2020. CsrA-mediated translational activation of *ymdA* expression in *Escherichia coli*. mBio 11:e00849-20. <https://doi.org/10.1128/mBio.00849-20>.
55. Pourciau C, Lai Y-J, Gorelik M, Babitzke P, Romeo T. 2020. Diverse mechanisms and circuitry for global regulation by the RNA-binding protein CsrA. Front Microbiol 11:601352. <https://doi.org/10.3389/fmicb.2020.601352>.
56. Fetherston JD, Schuetz P, Perry RD. 1992. Loss of the pigmentation phenotype in *Yersinia pestis* is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element. Mol Microbiol 6:2693–2704. <https://doi.org/10.1111/j.1365-2958.1992.tb01446.x>.
57. Surgalla MJ, Beesley ED. 1969. Congo red-agar plating medium for detecting pigmentation in *Pasteurella pestis*. Appl Microbiol 18:834–837. <https://doi.org/10.1128/am.18.5.834-837.1969>.
58. Timmermans J, Van Melderen L. 2009. Conditional essentiality of the *csrA* gene in *Escherichia coli*. J Bacteriol 191:1722–1724. <https://doi.org/10.1128/JB.01573-08>.
59. Bouvenot T, Dewitte A, Bennaceur N, Pradel E, Pierre F, Bontemps-Gallo S, Sebbane F. 2021. Interplay between *Yersinia pestis* and its flea vector in lipote metabolism. ISME J 15:1136–1149. <https://doi.org/10.1038/s41396-020-00839-0>.
60. Hinnebusch BJ. 2012. Biofilm-dependent and biofilm-independent mechanisms of transmission of *Yersinia pestis* by fleas. Adv Exp Med Biol 954:237–243. https://doi.org/10.1007/978-1-4614-3561-7_30.
61. Dewitte A, Bouvenot T, Pierre F, Ricard I, Pradel E, Barois N, Hujoux A, Bontemps-Gallo S, Sebbane F. 2020. A refined model of how *Yersinia pestis* produces a transmissible infection in its flea vector. PLoS Pathog 16:e1008440. <https://doi.org/10.1371/journal.ppat.1008440>.
62. Lorange EA, Race BL, Sebbane F, Hinnebusch BJ. 2005. Poor vector competence of fleas and the evolution of hypervirulence in *Yersinia pestis*. J Infect Dis 191:1907–1912. <https://doi.org/10.1086/429931>.
63. Ritzert JT, Minasov G, Embry R, Schipma MJ, Satchell KJF. 2019. The cyclic AMP receptor protein regulates quorum sensing and global gene expression in *Yersinia pestis* during planktonic growth and growth in biofilms. mBio 10:e02613-19. <https://doi.org/10.1128/mBio.02613-19>.
64. Heroven AK, Sest M, Pisano F, Scheb-Wetzel M, Steinmann R, Bohme K, Klein J, Munch R, Schomburg D, Dersch P. 2012. Crp induces switching of the CsrB and CsrC RNAs in *Yersinia pseudotuberculosis* and links nutritional status to virulence. Front Cell Infect Microbiol 2:158. <https://doi.org/10.3389/fcimb.2012.00158>.
65. Schachterle JK, Stewart RM, Schachterle MB, Calder JT, Kang H, Prince JT, Erickson DL. 2018. *Yersinia pseudotuberculosis* BarA-UvrY two-component regulatory system represses biofilms via CsrB. Front Cell Infect Microbiol 8:323. <https://doi.org/10.3389/fcimb.2018.00323>.
66. Pannuri A, Vakulskas CA, Zere T, McGibbon LC, Edwards AN, Georgellis D, Babitzke P, Romeo T. 2016. Circuitry linking the catabolite repression and Csr global regulatory systems of *Escherichia coli*. J Bacteriol 198:3000–3015. <https://doi.org/10.1128/JB.00454-16>.
67. Beauregard A, Smith EA, Petrone BL, Singh N, Karch C, McDonough KA, Wade JT. 2013. Identification and characterization of small RNAs in *Yersinia pestis*. RNA Biol 10:397–405. <https://doi.org/10.4161/rna.23590>.
68. Koo JT, Alleyne TM, Schiano CA, Jafari N, Lathem WW. 2011. Global discovery of small RNAs in *Yersinia pseudotuberculosis* identifies *Yersinia*-specific small, noncoding RNAs required for virulence. Proc Natl Acad Sci U S A 108:E709–E717. <https://doi.org/10.1073/pnas.1101655108>.
69. Schiano CA, Koo JT, Schipma MJ, Caulfield AJ, Jafari N, Lathem WW. 2014. Genome-wide analysis of small RNAs expressed by *Yersinia pestis* identifies a regulator of the Yop-Ysc type III secretion system. J Bacteriol 196:1659–1670. <https://doi.org/10.1128/JB.01456-13>.
70. Pannuri A, Yakhnin H, Vakulskas CA, Edwards AN, Babitzke P, Romeo T. 2012. Translational repression of NhaR, a novel pathway for multi-tier regulation of biofilm circuitry by CsrA. J Bacteriol 194:79–89. <https://doi.org/10.1128/JB.06209-11>.
71. Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer HP. 2005. A Tn7-based broad-range bacterial cloning and expression system. Nat Methods 2:443–448. <https://doi.org/10.1038/nmeth765>.
72. Stoker NG, Fairweather NF, Spratt BG. 1982. Versatile low-copy-number plasmid vectors for cloning in *Escherichia coli*. Gene 18:335–341. [https://doi.org/10.1016/0378-1119\(82\)90172-x](https://doi.org/10.1016/0378-1119(82)90172-x).
73. Uliczka F, Pisano F, Kochut A, Opitz W, Herbst K, Stolz T, Dersch P. 2011. Monitoring of gene expression in bacteria during infections using an adaptable set of bioluminescent, fluorescent and colorigenic fusion vectors. PLoS One 6:e20425. <https://doi.org/10.1371/journal.pone.0020425>.
74. Obrist MW, Miller VL. 2012. Low copy expression vectors for use in *Yersinia* sp. and related organisms. Plasmid 68:33–42. <https://doi.org/10.1016/j.plasmid.2012.02.003>.
75. Kusmierek M, Heroven AK, Beckstette M, Nuss AM, Dersch P. 2019. Discovering *Yersinia*-host interactions by tissue dual RNA-Seq. Methods Mol Biol 2010:99–116. https://doi.org/10.1007/978-1-4939-9541-7_8.
76. Yakhnin AV, Yakhnin H, Babitzke P. 2012. Gel mobility shift assays to detect protein-RNA interactions. Methods Mol Biol 905:201–211. https://doi.org/10.1007/978-1-61779-949-5_12.
77. Martinez-Chavarria LC, Sagawa J, Irons J, Hinz AK, Lemon A, Graca T, Downs DM, Vadyvaloo V. 2020. Putative horizontally acquired genes, highly transcribed during *Yersinia pestis* flea infection, are induced by hyperosmotic stress and function in aromatic amino acid metabolism. J Bacteriol 202:e00733-19. <https://doi.org/10.1128/JB.00733-19>.
78. Lemon A, Cherzan N, Vadyvaloo V. 2020. Influence of temperature on development of *Yersinia pestis* foregut blockage in *Xenopsylla cheopis* (Siphonaptera: Pulicidae) and *Oropsylla montana* (Siphonaptera: Ceratophyllidae). J Med Entomol <https://doi.org/10.1093/jme/tjaa113>.
79. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.